Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating crohn's disease and related conditions and infections

A Crohn's disease, composition technology, applied in the direction of drug combination, application, pharmaceutical formulation, etc., can solve the problem of delay in curing time, taking weeks or months, etc.

Inactive Publication Date: 2015-04-22
高拉夫·阿格拉沃尔
View PDF26 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Anti-Mycobacterium paratuberculosis (anti-MAP) therapy can successfully cure Crohn's disease, however time to cure can be delayed and may even take weeks or months to induce remission

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating crohn's disease and related conditions and infections
  • Compositions and methods for treating crohn's disease and related conditions and infections
  • Compositions and methods for treating crohn's disease and related conditions and infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0158] Example 1: Treatment of Crohn's associated fistula by administering the "triple combination therapy" of the present invention Exemplary treatment

[0159] A 32-year-old (yr) man with a 3-year history of Crohn’s disease (CD) presented with diarrhea, urgency, perianal tenderness, and discharge from a high left posterior fistula and right anterior fistula. With a'drain line' in place. The entire colon is inflamed, with Crohn's ulcer destroying the colonic haustration area. During the combination therapy, the'leakage line' is removed. At the 6th week, it was confirmed by MRI that the two fistulas were completely healed, with only scarring. Inflammation markers are normal and the patient continues anti-MAP therapy.

[0160] A 32-year-old woman with a 22-year history of CD was complicated by a rectal-vaginal fistula. She had severe pain during intercourse and had intestinal gas passing into the vagina during bowel emptying. The patient also reported frequent and urgent bowel...

Embodiment 2

[0161] Example 2: Treatment of Crohn's associated fistula by administering the "triple combination therapy" of the present invention Exemplary treatment

[0162] In an alternative embodiment, the treatment of the invention for patients with confirmed CD (+ / - fistula) comprises a combination of the following:

[0163] - Infliximab (5mg / kg, as an intravenous induction regimen at 0, 2 and 6 weeks (and then if necessary, a 5mg / kg maintenance regimen every 8 weeks, typically, the number of administrations is 3 to 9 Within the scope).

[0164] -Continuously starting from week 0 Anti-MAP therapy (Typically maintained for 3 months to 2 years or more).

[0165] In an alternative embodiment, in adults, this would be clofazimine, 100 mg / day; rifabutin, 450-600 mg / day; clarithromycin, 1 g / day; and another 400-800 Metronidazole at mg / day or ethambutol at 800 mg / day or pyrazinamide at 500 mg to 2 gm, depending on the adverse effects.

[0166] In an alternative embodiment, in children, this woul...

Embodiment 3

[0168] Example 3: Treatment of Crohn's associated fistula by administering the "triple combination therapy" of the present invention Exemplary treatment

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNFα composition, or a composition capable of down-modulating TNFα activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.

Description

Technical field [0001] The present invention generally relates to medicine as well as gastroenterology, pharmacology and microbiology. In an alternative embodiment, the present invention provides a method for treating, ameliorating, and preventing Crohn's disease (or Crohn's syndrome, terminal or distal ileitis or limitation of mammals) Enteritis) or "triple combination" therapy for related disorders and conditions, such as paratuberculosis in mammals, or Johne's disease, including genetic predisposition disorders and chronic disorders, in which the intestinal The microbe or bacterial flora is at least one causative factor or symptom producing factor; and a composition for implementing the therapy. In alternative embodiments, the methods and compositions of the present invention include or include the use of an active agent capable of inhibiting or eradicating the double infection of the microbiota that causes Crohn's disease or paratuberculosis infection in mammals, medicament...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P31/04A61P1/00
CPCA61K33/00A61K39/40A61K39/3955A61K31/496A61K39/39533A23C9/123A61K31/435A23G9/32A61K31/498A61K31/133A61K31/4164A61K31/7048A61K2039/505A23G4/06A23G3/36A61P1/00A61P1/04A61P29/00A61P31/04A61P37/06A61P43/00Y02A50/30A61K39/00A61K39/395
Inventor 高拉夫·阿格拉沃尔
Owner 高拉夫·阿格拉沃尔
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com